Nutritional Perspectives to Coronavirus Disease 2019 (COVID-19) Susceptibility and Severity: a review of the roles of vitamin D and C
Keywords:
cytokine storm, Vitamin C, Vitamin D, SARS-CoV-2, COVID-19Abstract
Background: Coronavirus disease 2019 (COVID-19) which was declared a global pandemic on March 11, 2020 is known to have affected more than 108 million people with more than 2 million deaths worldwide as at February 2021. The pathophysiology of disease severity is governed by a cytokine storm which could potentially be modulated by certain vitamins such as vitamins D and C with immunomodulatory and anti-inflammatory properties. The mechanisms underpinning the susceptibility to and severity of the disease when these nutrients that have shown anti-inflammatory properties are deficient is yet to be fully elucidated.
Objectives: The aim of this review was to explore the plausible mechanisms through which vitamin D and C can influence risk of SARS-CoV-2 infection and progression to severe symptomatic form of COVID-19.
Method: We performed a literature search to review the pathophysiology of COVID-19 as well as effects of supplemental vitamin D and C on risk of infection, disease progression and severity.
Results: Randomised control trials which administered high doses of vitamin D and C, have shown demonstrable beneficial effects in COVID-19 patients. Although there is no recommended dose of vitamin D and C for COVID-19, maintaining optimum plasma concentration of vitamin D (100-150 nmol/L) and vitamin C (60-80 μmol/L) may prove beneficial. Doses of 50-125μg/day of vitamin D3 and 2-3g/day of vitamin C have proven effective in maintaining this optimum plasma concentration in COVID-19.
Conclusions: Together these studies suggest that high dose supplementation of vitamin D and C to maintain optimum plasma concentration have shown better outcome, reduced risk of progression and fatality even in severe cases of COVID-19.
Downloads
References
1. Guo G, Ye L, Pan K, Chen Y, Xing D, Yan K, et al. New Insights of Emerging SARS- CoV-2: Epidemiology, Etiology, Clinical Features, Clinical Treatment, and Prevention. Front Cell Dev Biol 2020; 8:410.
2.Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R. Features, Evaluation, and Treatment of Coronavirus (COVID-19). [Updated 2021 Mar 1]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan-; Available from:https://www.ncbi.nlm.nih.gov/boo
ks/NBK554776/
3.Mason RJ. Pathogenesis of COVID-19 from a cell biologic perspective. EurRespir J2020;55:2000607.
4.Koh HK, Geller AC, VanderWeele TJ. Deaths From COVID-19. JAMA2021; 325: 133- 134.
5.Abid MA, Nunley L, Abid MB. Could Coronavirus Disease 2019 (COVID-19) Render Natural Immunity to Re- infections? A Spotlight on theTherapeutic Pipeline. FrontImmunol 2020; 11:1294.
6.He Y, Wang J, Li F, Shi Y. Main Clinical Features of COVID-19 and Potential Prognostic and Therapeutic Value of the Microbiota in SARS-CoV-2
Infections. Front Microbiol 2020; 11:1302.
7.Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 2020; 8:420-422.
8.Clark A, Jit M, Warren-Gash C, Guthrie B, Wang HHX, Mercer SW, et al. Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling study. Lancet Glob Health 2020; 8:e1003-e1017.
9.Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet2020; 395:497- 506.
10.Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to- person transmission: a study of a family cluster. Lancet2020; 395:514-523.
11.Majumder J, Minko T. Recent Developments on Therapeutic and Diagnostic Approaches for COVID-19. AAPSJ2021; 23:14.
12.Hu B, Huang S, Yin L. The cytokine storm and COVID-19. JMed Virol 2021; 93:250-256.
13.Feng Y, Ling Y, Bai T, Xie Y, Huang J, Li J, et al. COVID-19 with Different Severities: A Multicenter Study of Clinical Features. Am J Respir Crit Care Med 2020; 201: 1380-1388.
14.Azhar EI, Hui DSC, Memish ZA, Drosten C, Zumla A. The Middle East Respiratory Syndrome (MERS). Infect Dis Clin North Am 2019; 33:891-905.
15.Perlman S, Netland J. Coronaviruses post- SARS: update on replication and pathogenesis. Nat Rev Microbiol 2009; 7:439-50.
16.Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell2020; 181:271-280.e8.
17.Zou X, Chen K, Zou J, Han P, Hao J, Han Z. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. FrontMed 2020; 14(2):185-192.
18.Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, et al. SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients. N Engl JMed 2020; 382:1177-1179.
19.Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, et al. A Novel Angiotensin-Converting EnzymeRelated Carboxypeptidase (ACE2) Converts Angiotensin I to Angiotensin 1-9. Circ Res2000; 87:e1-e9.
20.Hamming I, Timens W, Bulthuis MLC, Lely AT, Navis GJ, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS corona virus. A first step in understanding SARS pathogenesis. J Pathol2004; 203:631-637.
21.Moore JB, June CH. Cytokine release syndrome in severe COVID-19. Science2020; 368: 473-474.
22.Wang S, Zhou X, Zhang T, Wang Z. The need for urogenital tract monitoring in COVID-19. Nat Rev Urol 2020; 17:314- 315.
23.Chan JF, To KK, Tse H, Jin DY, Yuen KY. Inter species transmission and emergence of novel viruses: lessons from bats and birds. Trends Microbiol2013; 21:544-55.
24.Chan JF, Kok KH, Zhu Z, Chu H, To KK, Yuan S, et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect 2020; 9:221-236.
25.Song SD, Acharya KD, Zhu JE, Deveney CM, Walther-Antonio MRS, Tetel MJ, et al. Daily Vaginal Microbiota Fluctuations Associated with Natural Hormonal Cycle, Contraceptives, Diet, and Exercise. mSphere2020; 5:e00593-20.
26.Knoops K, Kikkert M, Worm SHEvd, Zevenhoven-Dobbe JC, van der Meer Y, Koster AJ, et al. SARS-Coronavirus Replication Is Supported by a Reticulovesicular Network of Modified Endoplasmic Reticulum. PLOS Biol2008; 6(9):e226.
27.Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, et al. The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. Ann Intern Med 2020; 172:577-582.
28.Wong SF, Chow KM, Leung TN, Ng WF, Ng TK, Shek CC, et al. Pregnancy and perinatal outcomes of women with severe acute respiratory syndrome. AmJ ObstetGynecol 2004; 191:292-297.
29.Wong CK, Lam CWK, Wu AKL, Ip WK, Lee NLS, Chan IHS, et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory
syndrome. ClinExp Immunol 2004; 136:95-103.
30.Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet2020; 395:1033-1034.
31.Wang Z, Xu X. scRNA-seq Profiling of Human Testes Reveals the Presence of the ACE2 Receptor, A Target for SARS- CoV-2 Infection in Spermatogonia, Leydig and Sertoli Cells. Cells 2020; 9:920.
32.Chen H, Guo J, Wang C, Luo F, Yu X, Zhang W, et al. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. Lancet2020; 395:809-815.
33.Su H, Lei C-T, Zhang C. Interleukin-6 Signaling Pathway and Its Role in Kidney Disease: An Update. Front Immunol 2017; 8:405.34.Hirano T.
Interleukin 6 and its Receptor: Ten Years Later. Int Rev Immunol 1998; 16:249-284.
35.Tanaka T, Narazaki M, Kishimoto T. Immunotherapeutic implications of IL- 6 blockade for cytokine storm. Immunotherapy2016; 8:959-70.
36.Christodoulou S, Goula T, Ververidis A, Drosos G. Vitamin D and Bone Disease. BioMed ResInt 2013; 2013:396541.
37.Gunville CF, Mourani PM, Ginde AA. The role of vitamin D in prevention and treatment of infection. Inflamm Allergy Drug Targets 2013; 12:239-245.
38.Xu J, Yang J, Chen J, Luo Q, Zhang Q, Zhang H . Vitamin Dalleviates lipopolysaccharide-induced acute lung injury via regulation of the renin-angiotens in system. Mol MedRep2017; 16:7432-7438.
39.Carpagnano GE, Di Lecce V, Quaranta VN, Zito A, Buonamico E, Capozza E, et al. Vitamin D deficiency as a predictor of poor prognosis in patients with acute respiratory failure due to COVID-19. J Endocrinol Invest2020; 44(4):765-771.
40.Maghbooli ZME, Shirvani A, Nasiri M, Pazoki M, Kafan S, Tabriz HM, et al. Vitamin D Sufficiency Reduced Risk for Morbidity and Mortality in COVID-19 Patients. Lancet2020. Available at SSRN: or .
41.Merzon E, Manor I, Rotem A, Schneider T, Vinker S, Golan Cohen A, et al. ADHD as a Risk Factor for Infection With Covid-19. JAttenDisord 2020; 0: 1087054720943271.
42.DAvolio A, Avataneo V, Manca A, Cusato J, De Nicolò A, Lucchini R, et al. 25- Hydroxyvitamin D Concentrations Are Lower in Patients with Positive PCR for SARS-CoV-2. Nutrients2020; 12:1359.
43.Munshi R, Hussein MH, Toraih EA, Elshazli RM, Jardak C, Sultana N, et al. Vitamin D insufficiency as a potential culprit in critical COVID-19 patients. J Med Virol 2021; 93: 733-740.
44.Sabetta JR, DePetrillo P, Cipriani RJ, Smardin J, Burns LA, Landry ML. Serum 25-Hydroxyvitamin D and the Incidence of Acute Viral Respiratory Tract Infections in Healthy Adults. PLOS ONE2010; 5: e11088.
45.Quesada-Gomez JM, Entrenas-Castillo M, Bouillon R. Vitamin D receptor stimulation to reduce acute respiratory distress syndrome (ARDS) in patients with coronavirus SARS-CoV-2 infections: Revised Ms SBMB 2020_166. J Steroid BiochemMolBiol 2020; 202:105719.
46.Rastogi A, Bhansali A, Khare N, Suri V, Yaddanapudi N, Sachdeva N, et al. Short term, high-dose vitamin D supplementation for COVID-19
disease: a randomised, placebo-controlled, study (SHADE study). Post graduate Medical Journal Published Online First: 2020.doi:10.1136/postgradmedj-2020-139065.
47.Murai IH, Fernandes AL, Sales LP, Pinto AJ, Goessler KF, Duran CSC, et al. Effect of a Single High Dose of Vitamin D3 on Hospital Length of Stay in Patients With Moderate to Severe COVID-19: A Randomized Clinical Trial. JAMA2021; 325:1053-1060.
48.Hernández JL, Nan D, Fernandez-Ayala M, García-Unzueta M, Hernández- Hernández MA, López-Hoyos M, et al. Vitamin D Status in Hospitalized Patients with SARS-CoV-2 Infection. JClin EndocrinolMetab2020; 106:e1343- e1353.
49.Di Rosa M, Malaguarnera M, Nicoletti F, Malaguarnera L. Vitamin D3: a helpful immuno-modulator. Immunology2011; 134: 123-39.
50.Parlak E, Ertürk A, Çağ Y, Sebin E, Gümüşdere M. The effect of inflammatory cytokines and the level of vitamin D on prognosis in Crimean-
Congo hemorrhagic fever. Int J Clin Exp Med 2015; 8:18302-10.
51.Bowie AG, Unterholzner L. Viral evasion and subversion of pattern-recognition receptor signalling. Nat Rev Immunol 2008; 8:911-22.
52.Barlow PG, Svoboda P, Mackellar A, Nash AA, York IA, Pohl J, et al. Antiviral activity and increased host defense against influenza infection elicited by the human cathelicidin LL-37. PLoS One 2011; 6:e25333.
53.Zhao Y, Ran Z, Jiang Q, Hu N, Yu B, Zhu L, et al. Vitamin D Alleviates Rotavirus Infection through a Microrna-155-5p Mediated Regulation of the TBK1/IRF3 Signaling Pathway In Vivo and In Vitro. Int JMol Sci2019; 20:3562.
54.Mahallawi WH, Khabour OF, Zhang Q, Makhdoum HM, Suliman BA. MERS- CoV infection in humans is associated with a pro-inflammatory Th1 and Th17 cytokine profile. Cytokine2018; 104:8- 13.
55.Kawai T, Akira S. Signaling to NF-κB by Toll- like receptors. Trends MolMed 2007; 13:460-469.
56.Hansdottir S, Monick MM, Lovan N, Powers L, Gerke A, Hunninghake GW. Vitamin D Decreases Respiratory Syncytial Virus Induction of NF-κBLinked Chemokines and Cytokines in Airway Epithelium While Maintaining the Antiviral State. JImmunol2010; 184:965-974.
57.Lei G-S, Zhang C, Cheng B-H, Lee C-H. Mechanisms of Action of Vitamin D as Supplemental Therapy for Pneumocystis Pneumonia. Antimicrob Agents Chemother 2017; 61: e01226-17.
58.Santoro D, Caccamo D, Lucisano S, Buemi M, Sebekova K, Teta D, et al. Interplay of vitamin D, erythropoiesis, and the renin-angiotensin system. Biomed Res Int2015; 2015:145828.
59.Heaney RP. Vitamin D--baseline status and effective dose. N Engl J Med 2012; 367: 77-8.
60.Gasmi A, Noor S, Tippairote T, Dadar M, Menzel A, Bjørklund G. Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic. Clin Immunol 2020; 215:108409.
61.Heuser G, Vojdani A. Enhancement of Natural Killer Cell Activity and T and B Cell Function by Buffered Vitamin C In Patients Exposed to Toxic Chemicals: The Role of Protein Kinase-C. ImmunopharmacolImmunotoxicol199 7; 19:291-312.
62.Mousavi S, Bereswill S, Heimesaat MM. Immunomodulatory and antimicrobial effects of vitamin C. Eur J Microbiol Immunol 2019; 9:73-79.
63.Carr AC, Maggini S. Vitamin C and Immune Function. Nutrients2017; 9: 1211.
64.Arvinte C, Singh M, Marik PE. Serum Levels of Vitamin C and Vitamin D in a Cohort of Critically Ill COVID-19 Patients of a North American Community Hospital Intensive Care Unit in May 2020: A Pilot Study. Med Drug Discov 2020; 8: 100064-100064.
65.Chiscano-Camón L, Ruiz-Rodriguez JC, Ruiz-Sanmartin A, Roca O, Ferrer R. Vitamin C levels in patients with SARS- CoV-2-associated acute respiratory distress syndrome. Crit Care 2020; 24:522.
66.Patterson T, Isales CM, Fulzele S. Low level of Vitamin C and dysregulation of Vitamin C transporter might be involved in the severity of COVID-19 Infection. Aging Dis2021; 12:14-26.
67.Marik PE, Hooper MH. Doctor-your septic patients have scurvy! Crit Care2018; 22: 23.
68.Zhang J, Rao X, Li Y, Zhu Y, Liu F, Guo G, et al. Pilot trial of high-dose vitamin C in critically ill COVID-19 patients. Ann Intensive Care 12021; 1:5.
69.Hemilä H, Chalker E. Vitamin C may reduce the duration of mechanical ventilation in critically ill patients: a meta- regression analysis. J Intensive Care2020; 8:15.
70.Blanco-Melo D, Nilsson-Payant BE, Liu WC, Uhl S, Hoagland D, Møller R, et al.. Imbalanced Host Response to SARS- CoV-2 Drives Development of COVID- 19. Cell2020; 181:1036-1045.e9.
71.Zhang Q, Bastard P, Liu Z, Le Pen J, Moncada-Velez M, Chen J, et al., 2020. Inborn errors of type I IFN immunity in patients with life-threatening COVID- 19. Science370(6515):eabd4570.
72.Kim Y, Kim H, Bae S, Choi J, Lim SY, Lee N, et al. Vitamin C Is an Essential Factor on the Anti-viral Immune Responses through the Production of Interferon- α/β at the Initial Stage of Influenza A Virus (H3N2) Infection. Immune network 2013; 13:70-74.
73.José RJ, Williams A, Manuel A, Brown JS, Chambers RC. Targeting coagulation activation in severe COVID-19 pneumonia: lessons from bacterial pneumonia and sepsis. Eur Respir Rev2020; 29:200240.
74.Tyml K. Vitamin C and Microvascular Dysfunction in Systemic Inflammation. Antioxidants (Basel) 2017; 6(3):49.
75.Hiedra R, Lo KB, Elbashabsheh M, Gul F, Wright RM, Albano J, et al. The use of IV vitamin C for patients with COVID-19: a case series. Expert RevAnti Infect ther 2020; 18:1259-1261.
76.Laforge M, Elbim C, Frère C, Hémadi M, Massaad C, Nuss P, et al. Tissue damage from neutrophil-induced oxidative stress in COVID-19. Nat Rev Immunol 2020; 20: 515-516.
77.Carr AC, Spencer E, Dixon L, Chambers ST. Patients with Community Acquired Pneumonia Exhibit Depleted Vitamin C Status and Elevated Oxidative Stress. Nutrients 2020; 12(5):1318.
78.May JM, Harrison FE. Role of vitamin C in the function of the vascular endothelium. Antioxid Redox Signaling2013; 19:2068-2083.
79.Chen Y, Luo G, Yuan J, Wang Y, Yang X, Wang X, et al. Vitamin C mitigates oxidative stress and tumor necrosis factor-alpha in severe community- acquired pneumonia and LPS-induced macrophages. Mediators Inflamm2014; 2014:426740.
80.Erol N, Saglam L, Saglam YS, Erol HS, Altun S, Aktas MS, et al. The Protection Potential of Antioxidant Vitamins Against Acute Respiratory Distress Syndrome: a Rat Trial. Inflammation2019; 42:1585-1594.
81.Colunga Biancatelli RML, Berrill M, Marik PE. The antiviral properties of vitamin C. Expert Rev Anti Infect Ther 2020; 18:99-101.
82.Gan R, Rosoman NP, Henshaw DJE, Noble EP, Georgius P, Sommerfeld N. COVID-19 as a viral functional ACE2 deficiency disorder with ACE2 related multi-organ disease. Med hypotheses 2020; 144:110024-110024.
83.Ma S, Sun S, Li J, Fan Y, Qu J, Sun L, et al. Single-cell transcriptomic atlas of primate cardiopulmonary aging. Cell Research 2020; 31:415432.
84.Fisher BJ, Kraskauskas D, Martin EJ, Farkas D, Wegelin JA, Brophy D, et al. Mechanisms of attenuation of abdominal sepsis induced acute lung injury by ascorbic acid. Am J Physiol Lung Cell Mol Physiol 2012; 303:L20-32.
85.EFSA Panel on Dietetic Products N, Allergies. Scientific Opinion on Dietary Reference Values for vitamin C. EFSA Journal2013; 11:3418.
86.Levine M, Wang Y, Padayatty SJ, Morrow J. A new recommended dietary allowance of vitamin C for healthy young women. Proc Natl Acad Sci U S A 2001; 98:9842- 6.
87.Maggini S MP, Cardim P, Newball CF, Sota Latino ER. Vitamins C, D and Zinc: Synergistic Roles in Immune Function and Infections. Vitam Miner2017; 6:167
Downloads
Published
Issue
Section
License
All articles published in the journal are licensed under a Creative Commons Attribution (CC BY) license(i.e CC Attribution-NonCommercial-ShareAlike 4.0), allowing others to share, distribute, and build upon the work, provided the original author(s) and source are properly cited. Authors retain the copyright of their work.
